CollPlant regains Nasdaq $1 bid price compliance
CollPlant’s shares traded at or above $1.00 for ten straight business days, restoring compliance with Nasdaq’s minimum bid price listing rule.
Rhea-AI Filing Summary
CollPlant Biotechnologies Ltd. (CLGN) reports that it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2), which calls for a minimum bid of $1.00 per share. Nasdaq confirmed that CollPlant’s ordinary shares closed at or above $1.00 for ten consecutive business days from September 4 to September 18, 2026, formally closing the prior deficiency matter that began with a notice on March 23, 2026. Management emphasizes the importance of maintaining the Nasdaq listing and links this milestone to its broader strategy, including the recently completed LightSolver acquisition in high-performance computing and continued development of its rhCollagen regenerative medicine platform.
Positive
- Nasdaq listing compliance restored, as shares met the $1.00 minimum bid price for ten consecutive business days, closing the prior deficiency matter and supporting continued trading under Nasdaq Listing Rule 5550(a)(2).
Negative
- None.
Key Figures
Minimum bid price requirement: $1.00 per share
Compliance measurement window: 10 business days
Deficiency notice date: March 23, 2026
+1 more
4 metrics
Minimum bid price requirement
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) continued listing requirement for CollPlant’s ordinary shares
Compliance measurement window
10 business days
Closing bid at or above $1.00 per share from September 4–18, 2026
Deficiency notice date
March 23, 2026
Date Nasdaq notified CollPlant its shares had traded below $1.00 for 30 consecutive business days
Consecutive days below minimum bid price
30 business days
Trading period before the March 23, 2026 Nasdaq deficiency notice
Key Terms
Nasdaq Listing Rule 5550(a)(2), minimum bid price, continued listing requirement, forward-looking statements, +2 more
6 terms
Nasdaq Listing Rule 5550(a)(2) regulatory
"regained compliance with Listing Rule 5550(a)(2), which requires the Company’s common stock"
minimum bid price market
"requires the Company’s common stock to maintain a minimum bid price of $1.00 per share"
The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.
continued listing requirement regulatory
"CollPlant has satisfied the continued listing requirement under Nasdaq Listing Rule 5550(a)(2)"
Rules a stock exchange sets that a publicly traded company must follow to keep its shares listed, such as minimum share price, market value, shareholder equity, and timely financial reporting. These rules matter to investors because failing them can lead to removal from the exchange, which can make shares harder to buy or sell and often lowers their value — like a club with membership requirements where losing eligibility restricts access and signals trouble.
forward-looking statements regulatory
"This press release may contain forward-looking statements within the meaning of the “safe harbor”"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
regenerative medicine medical
"CollPlant remains a leader in regenerative medicine, pioneering plant-derived recombinant human collagen"
A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.
high-performance computing technical
"strategic expansion into high-performance computing (HPC) and photonics"
A cluster of very powerful computers, special chips and fast networks designed to tackle huge, complex calculations far faster than a normal PC — like replacing a single delivery van with a synchronized fleet to move a city’s worth of packages. For investors, high-performance computing matters because it enables faster product development, more accurate simulations and data analysis, and new revenue streams for hardware, software and services, making firms that supply or use it potentially more competitive and scalable.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CollPlant Biotechnologies Ltd. (CLGN) announce in this Form 6-K?
CollPlant announced it regained compliance with Nasdaq Listing Rule 5550(a)(2), after its ordinary shares maintained a closing bid price of at least $1.00 per share for ten consecutive business days from September 4 to September 18, 2026.
Why was CollPlant (CLGN) previously non-compliant with Nasdaq’s minimum bid price rule?
Nasdaq issued a deficiency notice on March 23, 2026 stating that CollPlant’s ordinary shares had traded below the $1.00 minimum bid price requirement for the prior 30 consecutive business days, triggering a compliance review under Listing Rule 5550(a)(2).
How did CollPlant (CLGN) regain compliance with Nasdaq’s Listing Rule 5550(a)(2)?
Nasdaq staff determined that for the ten consecutive business days from September 4–18, 2026, CollPlant’s closing bid price was at or above $1.00 per share, satisfying the minimum bid price requirement and restoring compliance.
What does Nasdaq’s confirmation mean for CollPlant’s (CLGN) listing status?
Nasdaq has formally confirmed the compliance matter is closed, meaning CollPlant currently satisfies the continued listing criteria related to the $1.00 minimum bid price under Listing Rule 5550(a)(2), supporting the ongoing listing of its ordinary shares.
How does this compliance update relate to CollPlant’s broader strategy?
Management states that maintaining the Nasdaq listing is important for business collaborators and shareholders and highlights ongoing plans to advance LightSolver’s photonic computing and CollPlant’s rhCollagen regenerative medicine platform as part of its diversified roadmap.
AI-generated analysis. How Rhea-AI works. Not financial advice.
